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to the T&O reconstruction. Without availability of MRI 
markers for needle visualization, manual MR-based needle 
reconstruction could be challenging especially in tissues of 
similar signal intensities. Measurement of remaining 
interstitial needle length outside patient could open up a 
potential solution path. 
 
Conclusion: Despite minor distortions around centre of the 
magnet, MRI distortions do not play a major role in applicator 
reconstruction uncertainties. Both CT- and MR-based 
applicator reconstruction are feasible when used with 
applicator library, providing accurate source pathway 
reconstruction. Applicator holes for interstitial needles and 
physical measurement of needle outside patient could 
provide valuable information to improve the reconstruction 
accuracy. 
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Purpose or Objective: The aim of this work is to evaluate 
outcomes after adjuvant brachytherapy of the lip cancer 
after surgical resection with close (<5mm) or positive 
margins. 
 
Material and Methods: A total of 20 patients (3 women and 
17 men in median age of 65,5) diagnosed between 2010 ad 
2014 with clinical T1 – T2 N0 lip carcinoma were treated 
primarly by surgical tumor resection with or without 
lymphadenectomy. After histopathological result (40% 
positive, 60% close margins) they were qualified for adjuvant 
brachytherapy. At the discretion of the attending physician 
25% of patients were treated by high dose rate (HDR) and 75% 
by pulse dose rate (PDR) brachytherapy. The mean 
biologically effective dose (BED) given to the clinical target 
volume were 71,285 Gy (range 62,6 – 75 Gy). The mean 
follow up (counted from the end of BT course to the last 
control visit or recurrence) were 24 months. For statistical 
calculations we used the Kaplan-Meier method and the U 
Mann-Whitney test. 
 
Results: Sole patient in the group had nodal reccurence 6 
months after treatment. The rest of the patients had no 
evidence of recurrence during the follow up. Estimated 4-
year disease-free survival rate was 95%. The acute skin 
toxicity according to RTOG scale was 65%, 30% and 5% for 
grade I, II, and III respectively; the late skin toxicity was 25%, 
5% and 5% for grade I, II, and IV respecively. We also found a 
statistically significant correlation between the higher BED 
and appearance of acute toxicity greater than I grade 
(p=0,014) and occurrence of any late toxicity (p=0,047). 
 
Conclusion: Adjuvant brachytherapy in the treatment of the 
T1-T2 lip tumors achieves a long loco-regional control with 
relatively low toxicity and it may be taken into consideration 
for the adjuvant therapy of the lip cancer after surgical 
resection with close (<5mm) or positive margins. Such 
regimen allows to prevent reoperations along with large 
reconstructive surgery. 
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Purpose or Objective: Patients with head and neck cancers 
can develop recurrences in previously treated areas, which 
usually involve the neighbor carotid artery. In the majority of 
these patients a complete surgical resection is not possible, 
R1/R2 resections are frequent. We proved the feasibility and 
long-term outcome of perioperative intensity modulated 
brachytherapy (IMBT) as a salvage treatment option for 
advanced neck metastases in combination of carotid artery 
preservation. 
 
Material and Methods: From 2006 to 2014, nine patients at 
the University Hospital of Schleswig-Holstein Campus Luebeck 
had received an interdisciplinary salvage treatment with 
debulking surgery and perioperative HDR-IMBT for advanced 
recurrent neck metastases. Median age was 53 years, range: 
38- 66, the mean follow-up was 66 months. Surgery was 
performed with primary wound closure in seven patients, 
while myocutaneus flap was used in two patients. Active 
phase of IMBT started 4-12 days following surgery. The 
prescription dose was 2.5Gy twice daily (average total dose: 
27Gy, range: 15-30Gy). Dose non-homogeneity ratio (DNR) 
never exceeded 0.42. We used the manual dose-volume 
optimization method and planned biologicaly correct 
hot/cold spot areas within the dose distribution. The 
reference isodose was defined within a maximum of 10 mm 
lateral distance from the interstitial tube and the Dmax was 
defined in 400% on the catheter surface. 
 
Results: For initial treatments, all patients received previous 
surgery; eight patients received also external beam radiation 
with an average dose of 64Gy. Two and five year overall 
survival estimates were 78% and 67% respectively. The 
median survival rate was 65 months. Only two patients had a 
second neck recurrence after 62 and 65 months. Early 
toxicities (grade I-II) recorded in four patients and were 
limited to local edema and skin infection, no treatment 
related grade 3 or 4 toxicities recorded. 
 
Conclusion: Salvage debulking surgery combined with 
perioperative HDR-IMBT seems to be feasible and safe 
treatment option for selected recurrent neck metastases with 
minimal treatment related toxicities. 
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Purpose or Objective: To assess the feasibility, safety and 
clinical outcome of MRI based and ultrasound guided high-
dose-rate interstitial brachytherapy technical in isolated 
lymph node metastases from different solid cancers. 
 
Material and Methods: From January 2013 to May 2014, 11 
patients (six males and four females) with isolated nodal 
metastases were treated with MRI based and ultrasound 
guided high-dose-rate brachytherapy. All patients had 
previously been treated with radical radiotherapy or 
chemoradiation with or without surgery. Seven lymph node 
metastases were cervical, three metastases were at the 
supraclaviculares, one metastasis located at a left inguinal 
nodal. Pathologically, six metastases were squamous 
carcinoma, three were small cell cancer and two were adeno 
carcinoma. The mean lesion diameter was 38.5 mm (range 
21.0- 78.0 mm). The brachytherapy were achieved by 
inserting the titanium needle to the target, avoiding vascular 
and organ injury under the ultrasound guidance, following by 
MRI scanning and delineating the targets. The metastases 
were treated by single-fraction irradiation using the 
afterloading technique using an Iridium-192 radiation source. 
The prescribed salvage dose of brachytherapy was 5 
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Gy/fraction, twice- daily to a total dose of 10-20 Gy (one 
week apart) according to the dose of the external beam 
radiotherapy. The total dose ranged from 76-84 Gy when 
transformed to EQD2 models. Patients were followed up by 
contrast-enhanced CT or MRI 4 weeks and then every 3 
months after the end of treatment. The primary end point 
was local tumor control. Secondary end points of the adverse 
events, distant metastases and progression-free survival were 
also included. 
 
Results: The first follow-up examination after 4 weeks 
revealed 10/11 coverage of all nodal metastases treated. 
There was no peri-interventional mortality or major 
complications. The mean follow-up period was 12.2 months 
(range 7–15 months). After a median follow up of three 
months, the median local tumor control was 90%. 2 out of 10 
patients (20%) showed local tumor progression 6 and 8 
months after brachytherapy. 2 patients (20%) who died of 
distant metastasis. The grade III-IV complications occurred in 
1 patient (10%). The mean progression-free interval was 13 
months (range 6–16 months).  
 
Conclusion: We consider that the interstitial brachytherapy 
technical will provide a relative high and accurate dose 
irradiation to bulky lymph node metastasis for improving the 
local tumor control in patients with different solid cancers. 
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Purpose or Objective: Commissioning of HDR brachytherapy 
treatment equipment is essential to avoid errors and assure 
quality. However, it is estimated that worldwide, less than 
one-quarter of centres undertake robust local commissioning 
tests at installation [1], important checks may be omitted 
[2], or systematic errors may remain [3]. The purpose of this 
work is to: (i) reinforce the need for local HDR commissioning 
and propose a list of recommended tests; (ii) publish results 
of the commissioning for a new-to-market HDR brachytherapy 
system from two centres. 
 
Material and Methods: A literature review was conducted on 
existing guidance for HDR system commissioning, HDR 
treatment errors and known factors affecting sub-optimal 
quality. The case for robust local commissioning of HDR 
equipment was assessed in terms of mitigating potential 
errors and improving quality of treatment delivery. A 
schedule of required commissioning tests was established and 
implemented at two centres, in England and Germany, for 
the commissioning of a new HDR brachytherapy treatment 
system, SagiNova (Eckert & Ziegler Bebig GmbH) with Co-60 
sources. 
 
Results: Evidence was found that errors do occur [4], 
particularly in the absence of robust commissioning and QC. 
There is little contemporary guidance for commissioning of 
HDR brachytherapy treatment equipment, which is required 
to build on the QC guidance in ESTRO Booklet No. 8 from 
2004. The table provides our proposal for efficient, robust, 
and easily implemented commissioning tests. For the 
SagiNova system, results from the two centres showed 
satisfactory performance in all tests. The mean error for 
source dwell positions in straight catheters was 0.5 mm (±0.5 
mm k=2) and in clinical treatment applicators was 0.6 mm 
(±1.0 mm k=2) compared to TPS planned positions. The ‘end 
to end’ system check with IPEM ‘BRAD’ system [5] had 
prescription point <0.4% (±2.5% k=2) and 97% gamma pass 
rate (3%, 2mm) compared to TPS calculations. By comparing 
results between centres a quality improvement was 
identified and implemented comprising an update of the 
dwell-position database at one centre. 
 
 
Conclusion: It is not sufficient to rely on type-testing by 
manufacturers and instead local commissioning must be 
implemented to assure quality and mitigate the risk of 
treatment errors in HDR brachytherapy. Suitable tests are not 
always performed and a schedule of minimum commissioning 
tests has been proposed. The first two installations of the 
new SagiNova HDR system demonstrated clinically acceptable 
results. An improvement of the source dwell database was 
identified, confirming the value of interdepartmental checks 
and robust commissioning. 
[1] Personal communication with HDR manufacturer,  
[2] Nisbet et al Radiother Oncol 106(sup 2):2013,  
[3] Palmer et al Br J Radiol 87(1041):2014,  
[4] ASAHI SHIMBUN 2014, AJ201312260063 
[5] Palmer et al Radiother Oncol 114(2):2015 
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Purpose or Objective: To simplify technical design of 
brachytherapy water phantom for performing absolute 
dosimetry using standard instruments and equipment 
available in radiotherapy department. To perform absolute 
measurements for source-to-ionization chamber distance ~ 4 
cm. 
 
Material and Methods: CNMC WP-380 water tank used for 
locating ionization chamber and the holder of the radioactive 
source. To minimize dimensional correction factors for 
ionization chamber it was taken 0,125 cm3 PTW 31010 
ionization chamber. For reducing uncertainty of the source 
position inside mould probe we used “curved catheter” 
method in the design of the catheter holder to make an 
effect of “pressing down” the end part of cable to lower wall 
of the probe. Holder designed in this way that amount of 
other than water surrounding source material was maximally 
reduced. Source-to-ionization chamber distance was set by 
